NCT07303283 2026-03-05
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
Guangxi Medical University
Phase 2 Not yet recruiting
Clinical Trials
7 trialsNCT07331428 2026-01-09
MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06987123 2025-05-23
TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06900218 2025-04-02
PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT06331845 2024-03-26
Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT05484375 2022-08-02
Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Not yet recruiting
NCT03503136 2018-05-11
NX-NPC
Sun Yat-sen University
Phase 3 Not yet recruiting